Significant portal hypertension
Conditions
Interventions
Gold Standard:Liver biopsy and HVPG measurements
Index test:1) Blood routine: Hb, Hct, RBC, WBC, N, PLT
2) Blood biochemistry
Liver function: ALT, AST, ALP, GGT, TB, DB, ALB, TP, TBA
Renal function: BUN, SCr, UA
3) Liver stiffness and spleen stiffness
Sponsors
Center for Infectious Diseases, West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) 18= age< 70 years old, male or female; 2) Compensated cirrhosis caused by various causes, with imaging evidence to clearly diagnose cirrhosis 3) Voluntarily participate in this clinical trial and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1) Contraindications to upper gastrointestinal endoscopy; 2) Those who have mental illness or other reasons and cannot cooperate with treatment; 3) Those who need to receive other anticoagulation for treatment reasons; 4) Those with allergies, known allergies to blood products, test drugs (namumostat mesylate, heparin sodium) and their excipients; 5) Pregnant, recently preparing for pregnancy, lactating women; 6) Those who have participated in other clinical trials in the past 1 month; 7) Those who are considered by the investigator to be unsuitable for inclusion; 8) Patients with decompensated liver cirrhosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver stiffness;Spleen hardness;Accuracy;Sensitivity;Specificity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Positive predicative value;Negative predictive value; | — |
Countries
China
Contacts
Public ContactYayu Gao
West China Hospital, Sichuan University
Outcome results
None listed